Giovanni Amato
About
Giovanni Amato is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology and Molecular Biology.
According to data from OpenAlex, Giovanni Amato has authored 89 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Endocrinology, Diabetes and Metabolism, 25 papers in Oncology and 21 papers in Molecular Biology. Recurrent topics in Giovanni Amato's work include Thyroid Disorders and Treatments (21 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Growth Hormone and Insulin-like Growth Factors (12 papers). Giovanni Amato is often cited by papers focused on Thyroid Disorders and Treatments (21 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Growth Hormone and Insulin-like Growth Factors (12 papers). Giovanni Amato collaborates with scholars based in Italy, United States and United Kingdom. Giovanni Amato's co-authors include Carlo Carella, Gherardo Mazziotti, Antonio Bellastella, Luigi Saccà, Antonio Cittadini, F. Sorvillo, Sergio Fazio, Anna Maria Di Giacomo, Diana Giannarelli and Bernadette Biondi and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Cancer Research.
In The Last Decade
Giovanni Amato
85 papers receiving 3.2k citations
Peers
Giovanni Amato
Alois Gessl Austria
Myung‐Whun Sung South Korea
A. Koneti Rao United States
Lisa Menegazzo Italy
Piotr Witkowski United States
Philippe Morel Switzerland
Yan Liang China
Federica Genovese Denmark
Susana Amuchastegui Italy
Jun Asai Japan
Citations per year, relative to Giovanni Amato Giovanni Amato (= 1×)
peers
Alois Gessl
Countries citing papers authored by Giovanni Amato
Since
Specialization
Citations
This map shows the geographic impact of Giovanni Amato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giovanni Amato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giovanni Amato more than expected).
Fields of papers citing papers by Giovanni Amato
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Giovanni Amato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giovanni Amato. The network helps show where Giovanni Amato may publish in the future.
Co-authorship network of co-authors of Giovanni Amato
This figure shows the co-authorship network connecting the top 25 collaborators of Giovanni Amato. A scholar is included among the top collaborators of Giovanni Amato based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giovanni Amato. Giovanni Amato is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Giacomo, Anna Maria Di, Matteo Simonelli, Giovanni Amato, et al.. (2024). Roginolisib, an oral, highly selective and allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with uveal melanoma and advanced cancers.. Journal of Clinical Oncology. 42(16_suppl). 9597–9597.
2.
Giacomo, Anna Maria Di, Michele Del Vecchio, Pier Francesco Ferrucci, et al.. (2023). 1084MO Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial. Annals of Oncology. 34. S653–S654.
3.
Giacomo, Anna Maria Di, Giuseppe Rossi, Luana Calabrò, et al.. (2023). 123P A phase II study of nivolumab (N) plus ipilimumab (I) and ASTX727 or N plus I in PD-1/PD-L1 resistant melanoma or NSCLC patients: The run-in phase of the NIBIT Foundation ML1 study. Immuno-Oncology Technology. 20. 100595–100595.
4.
Giacomo, Anna Maria Di, Giovanni Amato, Michael Lahn, et al.. (2023). First-in-human (FIH) phase I dose escalation study (part A) of the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in uveal melanoma (part B).. Journal of Clinical Oncology. 41(16_suppl). 3110–3110.
5.
Musumeci, Teresa, Giulia Di Benedetto, Claudia Carbone, et al.. (2022). Intranasal Administration of a TRAIL Neutralizing Monoclonal Antibody Adsorbed in PLGA Nanoparticles and NLC Nanosystems: An In Vivo Study on a Mouse Model of Alzheimer’s Disease. Biomedicines. 10(5). 985–985.
6.
Giacomo, Anna Maria Di, Vanna Chiarion‐Sileni, Michele Del Vecchio, et al.. (2021). Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases. Clinical Cancer Research. 27(17). 4737–4745.
7.
Amato, Giovanni, Maria Aurora Grimaudo, Carmen Alvarez‐Lorenzo, et al.. (2020). Hyaluronan/Poly-L-lysine/Berberine Nanogels for Impaired Wound Healing. Pharmaceutics. 13(1). 34–34.
8.
Giacomo, Anna Maria Di, Michele Del Vecchio, Pier Francesco Ferrucci, et al.. (2020). 1081MO Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial. Annals of Oncology. 31. S734–S734.
9.
Grimaudo, Maria Aurora, Giovanni Amato, Claudia Carbone, et al.. (2019). Micelle-nanogel platform for ferulic acid ocular delivery. International Journal of Pharmaceutics. 576. 118986–118986.
10.
Maccalli, Cristina, Diana Giannarelli, Ornella Cutaia, et al.. (2017). Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients. OncoImmunology. 6(7). e1323618–e1323618.
11.
Licciardi, Mariano, Gianfranco Pasut, Giovanni Amato, et al.. (2012). PHEA-graft-polymethacrylate supramolecular aggregates for protein oral delivery. European Journal of Pharmaceutics and Biopharmaceutics. 84(1). 21–28.
12.
Amato, Giovanni, Gherardo Mazziotti, F. Sorvillo, et al.. (2004). High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. Bone. 35(3). 785–791.
13.
Sorvillo, F., Gherardo Mazziotti, Antonella Carbone, et al.. (2003). Recombinant Human Thyrotropin Reduces Serum Vascular Endothelial Growth Factor Levels in Patients Monitored for Thyroid Carcinoma Even in the Absence of Thyroid Tissue. The Journal of Clinical Endocrinology & Metabolism. 88(10). 4818–4822.
14.
Amato, Giovanni, Gherardo Mazziotti, Mario Rotondi, et al.. (2002). Long‐term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clinical Endocrinology. 56(1). 65–71.
15.
Carella, Carlo, Gherardo Mazziotti, Filomena Morisco, et al.. (2001). Long-Term Outcome of Interferon-α-Induced Thyroid Autoimmunity and Prognostic Influence of Thyroid Autoantibody Pattern at the End of Treatment. The Journal of Clinical Endocrinology & Metabolism. 86(5). 1925–1929.
16.
Rotondi, Mario, Giovanni Amato, Bernadette Biondi, et al.. (2000). Parity as a Thyroid Size-Determining Factor in Areas with Moderate Iodine Deficiency. The Journal of Clinical Endocrinology & Metabolism. 85(12). 4534–4537.
17.
Rotondi, Mario, Giovanni Amato, Andrea Del Buono, et al.. (2000). Postintervention Serum TSH Levels May Be Useful to Differentiate Patients Who Should Undergo Levothyroxine Suppressive Therapy After Thyroid Surgery for Multinodular Goiter in a Region with Moderate Iodine Deficiency. Thyroid. 10(12). 1081–1085.
18.
Amato, Giovanni, et al.. (1996). Recombinant human growth hormone treatment at low doses does not significantly change thyroid function in growth hormone deficient adults. Journal of Endocrinological Investigation. 19(8). 563–566.
19.
Carella, Carlo, Giovanni Amato, Bernadette Biondi, et al.. (1995). Longitudinal Study of Antibodies against Thyroid in Patients Undergoing Interferon-α Therapy for HCV Chronic Hepatitis. Hormone Research. 44(3). 110–114.
20.
Scotto, Gaetano, et al.. (1992). HCV Infections in Dialysis Patients. The Nephron journals/Nephron journals. 61(3). 320–321.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Alois Gessl Breakdown of academic impact, for papers by Myung‐Whun Sung Breakdown of academic impact, for papers by A. Koneti Rao Breakdown of academic impact, for papers by Lisa Menegazzo Breakdown of academic impact, for papers by Piotr Witkowski Breakdown of academic impact, for papers by Philippe Morel Breakdown of academic impact, for papers by Yan Liang Breakdown of academic impact, for papers by Federica Genovese Breakdown of academic impact, for papers by Susana Amuchastegui Breakdown of academic impact, for papers by Jun Asai